IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

This study tests a combination of a new immunotherapy drug (IBI363, which activates the immune system against cancer) with standard chemotherapy as a pre-surgery treatment (neoadjuvant therapy) for patients with Stage III non-small cell lung cancer (NSCLC) that cannot be surgically removed initially. **You may be eligible if...** - You are 18 or older with good overall health (ECOG 0-1) - You have Stage III NSCLC (squamous or non-squamous) that is not surgically removable - This is your first treatment — you have not had any prior chemotherapy, immunotherapy, or radiation - You have adequate heart, liver, and kidney function - Your tumor does not have specific genetic mutations (EGFR, ALK) that have approved targeted therapies **You may NOT be eligible if...** - Your tumor has driver mutations (like EGFR or ALK) that are targeted by approved drugs - You have active autoimmune disease or are on immune-suppressing medications - You have had a recent heart attack, stroke, or uncontrolled high blood pressure - You have active hepatitis B, C, or HIV - You have current or prior lung inflammation (pneumonitis or pulmonary fibrosis) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.